Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Joincare Pharmaceutical Group Industry Co., Ltd. has obtained the drug registration certificate for its inhaled powder and mist of salmeterol and fluticasone.
Published Time：
2024-06-14
On June 12, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. announced that it had received the Drug Registration Certificate issued by the National Medical Products Administration, marking the official approval of the marketing of its salmeterol/fluticasone propionate inhalation powder (hereinafter referred to as "the Product"). This news not only brings huge market opportunities for HealthGen but also provides a new treatment option for relevant patients.
The combined salmeterol and fluticasone propionate inhalation powder is independently developed by HealthGen. Salmeterol is a long-acting β2-agonist that can lastingly dilate the bronchi and improve respiratory conditions; while fluticasone propionate is a glucocorticoid that can effectively control inflammation and reduce acute attacks. This combined medication is the gold standard for asthma treatment and has been widely recognized and applied.
HealthGen first submitted the registration application for this product in February 2023. As of the announcement date, the company has cumulatively invested approximately RMB 88.9057 million in the research and development of this product, demonstrating HealthGen's emphasis on and determination towards innovative drug research and development.
The original research product of salmeterol/fluticasone propionate inhalation powder is Seretide® from GlaxoSmithKline (GSK). Since its first approval for import into China in 2001, this product has become an important product for the treatment of asthma and COPD. According to GSK's 2023 annual report, the global sales of Seretide® were approximately £1.139 billion. In China, according to IQVIA's statistics, the terminal sales of Seretide® in 2023 were approximately RMB 783 million.
Currently, no other company's product has been approved for marketing in China. Four other companies have submitted marketing authorization applications, but none have been approved yet. HealthGen's product is expected to occupy an important position in the market, providing new solutions for patients.
In the future, HealthGen will continue to increase its R&D investment, promote the research and development and marketing of more innovative drugs to meet the needs of patients and enhance the company's market competitiveness. At the same time, the company will strictly abide by relevant national laws and regulations, ensure the quality and safety of drugs, and provide patients with higher quality medical services.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.